Clinical Performance of an Alkasite-based Restorative Material

March 12, 2024 updated by: Tarek Mohamed Tawfik Alagamawy, Cairo University

Clinical Performance of an Alkasite-based Restorative Material Versus Highly Viscous Glass Ionomer in Occlusal Cavities After 18 Months: A Randomized Clinical Trial

The evolution of restorative dental materials and technology has enabled the use of tooth-colored restorative materials in dental restorations, with all dentists hoping for the presence of materials that combine biocompatible qualities and aesthetics . Although resin composite materials' mechanical and aesthetic properties have greatly improved over the past 20 years, research is currently on to find ways to prevent secondary caries from forming beneath and at the margins of restorations. In order to circumvent these problems, there is a growing tendency towards the use of resin-based bioactive and remineralizing restorative materials to strengthen and lengthen the lifespan of bonded dental restorations.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

The evolution of restorative dental materials and technology has enabled the use of tooth-colored restorative materials in dental restorations, with all dentists hoping for the presence of materials that combine biocompatible qualities and aesthetics . Although resin composite materials' mechanical and aesthetic properties have greatly improved over the past 20 years, research is currently on to find ways to prevent secondary caries from forming beneath and at the margins of restorations. In order to circumvent these problems, there is a growing tendency towards the use of resin-based bioactive and remineralizing restorative materials to strengthen and lengthen the lifespan of bonded dental restorations.Glass ionomer is one of the most commonly used materials in dental restorations. One of the most important properties of GICs is their ability to release fluoride and recharge. Other reasons for GIC's widespread use in the dental field are its beneficial properties such as adhesion to tooth structure, equivalent coefficient of thermal expansion of teeth, and excellent biocompatibility. However, they have disadvantages such as severe wear, high solubility, poor mechanical properties, and limited occlusal force resistance. Today's generation GICs have tried to address these disadvantages by incorporating a fast setting reinforced glass ionomer that should offer protection during the early maturation process and enhance strength and surface hardness. It has been improved by changes in the ratio of powder to liquid, particle size and dispersion. As a result, highly viscous glass ionomer (HVGIC) is available on the market. In the last few years, we have seen the introduction of a glass ionomer encapsulated with high mechanical properties as claimed by the manufacturer. The GIC, which is characterized by its rapid setting and high viscosity, could serve as an alternative to amalgam and composite restorations in cavities of class I and II for permanent teeth.

For decades, dentists have been looking for a material that is affordable, fluoride releasing, easy to apply, strong, and aesthetically pleasing. A novel bioactive, alkasite material has been introduced enabling quick and efficient minimally invasive treatment. . It is a self-curing radiopaque material for direct treatment of anterior and posterior cavities. It is claimed as a tooth coloured, bioactive, durable material to be rendered as the new alternative to amalgam for permanent Class I and II restorations. It also promotes remineralization and prevents demineralization with an advanced ion-releasing system. When the pH drops because of the growth of the cariogenic bacteria, it releases hydroxide ions to help restore the pH balance. Hydroxide ions help to prevent tooth structure from being demineralized. The fluoride and calcium ions released help remineralize the tooth structure and prevent secondary caries.

Study Type

Interventional

Enrollment (Estimated)

68

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • • Patients with carious occlusal lesions with underlying dark shadow in posterior teeth (lower first molar) with ICDAS score 4.

    • Patients with at least 20 teeth under occlusion.
    • Age: 16-55 years.
    • Co-operative patients approving to participate in the trial.

Exclusion Criteria:

  • • Patients younger than 16 years old or older than 55 years old.

    • Extensive occlusal lesions.
    • Teeth with signs and symptoms of irreversible pulpitis or pulp necrosis.
    • Teeth supporting removable prostheses, or orthodontic appliances.
    • Candidates with parafunction or bruxism.
    • Candidates with systemic diseases or disabilities that may affect participation.
    • Drug-induced xerostomia.
    • Heavy smoking.
    • Pregnancy.
    • Lack of compliance.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Centio Forte (Ivoclar).

A new class of bioactive "alkasite" restorative materials has been released in the market. They're composed of three main filler types: salinized inert barium aluminium silicate glass, calcium barium aluminium fluorosilicate glass similar to glass-ionomers, and calcium fluorosilicate glass or "alkasite" glass. Cention N (Ivoclar Vivadent) was the first available material in the material in the form of powder/liquid, later on, Cention forte was released which is the modified capsulated form with a special adhesive system Marovic et al. (2022).

Cention has the ability to remineralize hard dental tissues through calcium and fluoride release and can also neutralize bacterial acids through hydroxide ions release Par et al. (2020).

A new Alkasite material has been introduced with superior strength and bioactive ion release where it is considered the new alternative to amalgam.
Active Comparator: Highly viscous glass ionomer

Glass-ionomer restorations (GI) are widely used in restorative dentistry. One of their advantages is their chemical adhesion to tooth structure. They also possess a fluoride-releasing property and biocompatibility. Although GIs are commonly used, they have some disadvantages. The most intractable problem with the conventional GIs is probably their lack of strength and toughness. In order to improve the mechanical properties of conventional GICs, reinforced GIs were developed. These reinforced GIs or now commonly known as highly viscous GIs provide improved mechanical properties and wear resistance, easier application allowing their use in posterior stress bearing cavity preparations Bakhadher et al.

(2019).

A new Alkasite material has been introduced with superior strength and bioactive ion release where it is considered the new alternative to amalgam.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Retention success rate % with modified USPH criteria
Time Frame: 18 months with; T0=Baseline, T1= 6 months follow up, T2=12 months follow up and T3= 18 months follow up.
retention of the restoration, with USPH criteria
18 months with; T0=Baseline, T1= 6 months follow up, T2=12 months follow up and T3= 18 months follow up.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Marginal adaptation with modified USPH criteria marginal discolouration, recurrent caries, anatomic form and postoperative sensitivity.
Time Frame: 18 months with; T0=Baseline, T1= 6 months follow up, T2=12 months follow up and T3= 18 months follow up.
marginal integrity of the restoration with USPH criteria
18 months with; T0=Baseline, T1= 6 months follow up, T2=12 months follow up and T3= 18 months follow up.
Postoperative sensitivity
Time Frame: 18 months with; T0=Baseline, T1= 6 months follow up, T2=12 months follow up and T3= 18 months follow up.
Degree of post operative sensitivity with USPH criteria
18 months with; T0=Baseline, T1= 6 months follow up, T2=12 months follow up and T3= 18 months follow up.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2024

Primary Completion (Estimated)

June 30, 2025

Study Completion (Estimated)

June 30, 2025

Study Registration Dates

First Submitted

March 1, 2024

First Submitted That Met QC Criteria

March 12, 2024

First Posted (Actual)

March 19, 2024

Study Record Updates

Last Update Posted (Actual)

March 19, 2024

Last Update Submitted That Met QC Criteria

March 12, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 14422021443228

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Caries, Dental

Clinical Trials on Centio Forte

Subscribe